| Title |
Delamanid: First Global Approval
|
|---|---|
| Published in |
Drugs, June 2014
|
| DOI | 10.1007/s40265-014-0241-5 |
| Pubmed ID | |
| Authors |
Nicola J. Ryan, Jin Han Lo |
| Abstract |
Delamanid, a nitro-dihydro-imidazooxazole derivative, has been developed by Otsuka Pharmaceutical for the treatment of multidrug-resistant tuberculosis (MDR-TB). Delamanid received its first global approval for the treatment of MDR-TB in the European Union (EU), for use in combination with optimised background therapy. It is also under review for marketing in Japan for MDR-TB, the first drug application filed in Japan for this indication. Delamanid has been granted orphan drug status in both the EU and Japan. This article summarizes the milestones in the development of delamanid leading to this first approval for MDR-TB. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 2 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 126 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | <1% |
| Russia | 1 | <1% |
| South Africa | 1 | <1% |
| Unknown | 123 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 21 | 17% |
| Student > Master | 18 | 14% |
| Researcher | 12 | 10% |
| Student > Bachelor | 12 | 10% |
| Student > Postgraduate | 9 | 7% |
| Other | 21 | 17% |
| Unknown | 33 | 26% |
| Readers by discipline | Count | As % |
|---|---|---|
| Chemistry | 22 | 17% |
| Medicine and Dentistry | 15 | 12% |
| Pharmacology, Toxicology and Pharmaceutical Science | 15 | 12% |
| Biochemistry, Genetics and Molecular Biology | 14 | 11% |
| Agricultural and Biological Sciences | 12 | 10% |
| Other | 12 | 10% |
| Unknown | 36 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 37. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 December 2023.
All research outputs
#1,061,168
of 25,097,836 outputs
Outputs from Drugs
#77
of 3,469 outputs
Outputs of similar age
#10,259
of 234,671 outputs
Outputs of similar age from Drugs
#1
of 46 outputs
Altmetric has tracked 25,097,836 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 3,469 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.7. This one has done particularly well, scoring higher than 97% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 234,671 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 46 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 99% of its contemporaries.